Literature DB >> 24160811

Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis.

Thuy B Tran1, Douglas Liou, Vijay G Menon, Nicholas N Nissen.   

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a dismal prognosis. When diagnosed in advanced stages of the disease, the outcomes of surgical resection are not well understood. The objective of this study is to determine the impact of surgery in patients with advanced ACC. Using the Surveillance, Epidemiology and End Results database, we identified patients diagnosed with Stage III and IV ACC between 1988 and 2009. A total of 320 patients with Stage III and IV disease were included in our analysis. In patients treated with surgical resection, the Stage III 1- and 5-year survival rates were 77 and 40 per cent, respectively, whereas the Stage IV 1- and 5-year survival rates were 54 and 27.6 per cent, respectively. Patients treated without surgery had poor survival at 1 year for both Stage III (13%) and Stage IV (16%) (P < 0.01 compared with the surgical groups). Lymph node dissection was performed in 26 per cent of the patients with advanced ACC and was associated with improved survival in univariate analysis of Stage IV patients. Overall, our results indicate that favorable survival outcomes can be achieved even in patients with Stage III and IV disease and surgery should be considered in patients with advanced ACC.

Entities:  

Mesh:

Year:  2013        PMID: 24160811

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  13 in total

1.  Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease.

Authors:  Masha Livhits; Ning Li; Michael W Yeh; Avital Harari
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

2.  Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study.

Authors:  Naris Nilubol; Dhaval Patel; Electron Kebebew
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

3.  Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?

Authors:  Jon M Gerry; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason D Prescott; Tracy S Wang; Jason A Glenn; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Ioannis Hatzaras; Rivfka Shenoy; Timothy M Pawlik; Jeffrey A Norton; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2016-09-02       Impact factor: 5.344

4.  Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival.

Authors:  Victor Srougi; Irina Bancos; Marilyne Daher; Jeffrey E Lee; Paul H Graham; Jose A Karam; Andres Henriquez; Travis J Mckenzie; Alaa Sada; Isabelle Bourdeau; Jonathan Poirier; Anand Vaidya; Tiffany Abbondanza; Colleen M Kiernan; Sarika N Rao; Oksana Hamidi; Nirupa Sachithanandan; Ana O Hoff; Jose L Chambo; Madson Q Almeida; Mouhammed Amir Habra; Maria C B V Fragoso
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 6.134

5.  Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.

Authors:  Fabio Bagante; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2015-07-31       Impact factor: 3.454

6.  Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.

Authors:  Yuhree Kim; Georgios A Margonis; Jason D Prescott; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Douglas B Evans; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed I Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2016-04       Impact factor: 14.766

Review 7.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.

Authors:  Kerollos N Wanis; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2015-03-24       Impact factor: 2.754

8.  Conditional survival among patients with adrenal cortical carcinoma determined using a national population-based surveillance, epidemiology, and end results registry.

Authors:  Wen-jun Xiao; Yao Zhu; Bo Dai; Hai-liang Zhang; Guo-hai Shi; Yi-jun Shen; Yi-ping Zhu; Ding-wei Ye
Journal:  Oncotarget       Date:  2015-12-29

9.  Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades.

Authors:  Jan Calissendorff; Freja Calissendorff; Henrik Falhammar
Journal:  BMC Endocr Disord       Date:  2016-03-17       Impact factor: 2.763

Review 10.  Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment.

Authors:  Omair A Shariq; Travis J McKenzie
Journal:  Ther Adv Chronic Dis       Date:  2021-07-20       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.